Cargando…

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

BACKGROUND: The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncological drugs with metronomic temozolomide—version 3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halatsch, Marc-Eric, Kast, Richard E, Karpel-Massler, Georg, Mayer, Benjamin, Zolk, Oliver, Schmitz, Bernd, Scheuerle, Angelika, Maier, Ludwig, Bullinger, Lars, Mayer-Steinacker, Regine, Schmidt, Carl, Zeiler, Katharina, Elshaer, Ziad, Panther, Patricia, Schmelzle, Birgit, Hallmen, Anke, Dwucet, Annika, Siegelin, Markus D, Westhoff, Mike-Andrew, Beckers, Kristine, Bouche, Gauthier, Heiland, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349180/ https://www.ncbi.nlm.nih.gov/pubmed/34377985 http://dx.doi.org/10.1093/noajnl/vdab075

Ejemplares similares

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
por: Pruss, Maximilian, et al.
Publicado: (2020)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Targeting super-enhancers reprograms glioblastoma central carbon metabolism
por: Nguyen, Trang T.T., et al.
Publicado: (2021)

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
por: Pala, Andrej, et al.
Publicado: (2012)

A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen
por: Kast, Richard E., et al.
Publicado: (2020)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression
por: Dwucet, Annika, et al.
Publicado: (2021)

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen
por: Kast, Richard E, et al.
Publicado: (2017)

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
por: Karpel-Massler, Georg, et al.
Publicado: (2014)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen
por: Salacz, Michael E, et al.
Publicado: (2016)

Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells
por: Hasslacher, Sebastian, et al.
Publicado: (2018)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

Targeting cellular respiration as a therapeutic strategy in glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2023)

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
por: Kast, Richard E., et al.
Publicado: (2013)

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
por: Kast, Richard E, et al.
Publicado: (2017)

The effects of PI3K-mediated signalling on glioblastoma cell behaviour
por: Langhans, Julia, et al.
Publicado: (2017)

The limitations of targeting MEK signalling in Glioblastoma therapy
por: Selvasaravanan, Karthika D., et al.
Publicado: (2020)

A triple drug combination as a novel anti-glioma therapy?
por: Zhang, Yiru, et al.
Publicado: (2018)

Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme
por: Karpel-Massler, Georg, et al.
Publicado: (2010)

Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen
por: Kast, Richard E., et al.
Publicado: (2018)

IDH1 R132H predicts sensitivity to Bcl-xL inhibition-mediated programmed cell death
por: Karpel-Massler, Georg, et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems
por: Nguyen, Trang T. T., et al.
Publicado: (2020)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma
por: Thi Thu Nguyen, Trang, et al.
Publicado: (2020)

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2014)

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy
por: Ströbele, Stephanie, et al.
Publicado: (2015)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Zhang, Yiru, et al.
Publicado: (2018)

What Animal Cancers teach us about Human Biology
por: Kattner, Patricia, et al.
Publicado: (2021)

Killing Me Softly—Future Challenges in Apoptosis Research
por: Westhoff, Mike-Andrew, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_38gm3h9act93dcst877ni4m9r8